Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
Date:2/16/2010

(35,947,943) (52,845,121) Interest income 4,706 150,642 89,097 1,780,880 Net loss $(9,237,390) $(7,504,019) $(35,858,846) $(51,064,241) =========== =========== ============ ============ Basic and diluted net loss per share attributable to common stockholders $(0.34) $(0.28) $(1.33) $(1.92) ====== ====== ====== ====== Shares used in calculation of basic and diluted net loss per share attributable to common stockholders 27,286,667 26,652,187 27,015,271 26,650,126 ========== ========== ========== ========== VANDA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) December 31, December 31, 2009 2008 ---- ---- ASSETS Current assets: Cash and cash equivalents
'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
2. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
3. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
8. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
9. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
10. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 Avelas Biosciences, an in vivo ... announced today that it has initiated a Phase 1b ... women with primary, non-recurrent breast cancer undergoing surgery. In ... addition of Steven Chen , M.D., as vice ... dose escalation study will enroll up to 39 women ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
(Date:4/16/2015)... April 16, 2015 Fairleigh Dickinson ... V. Gulfo to become the Executive Director of ... FDU announced the kick-off of the Initiative for ... by Dr. Gulfo, under the Rothman Institute of ... Business) and in collaboration with FDU’s School of ...
(Date:4/16/2015)... 2015 Dana-Farber Cancer Institute and ... Resolution Bioscience, Inc. today announced the successful completion ... blood-based, clinic ready, Next Generation Sequencing (NGS) assay ... is the first to demonstrate the successful sequencing ... in blinded plasma samples and highlights the ability ...
Breaking Biology Technology:Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
... Immunotec,looks to the beginning of its twelfth year ... C.H. (Chuck) Roberts announces,his retirement from his role ... will continue his involvement with the corporation, both ... and as Co-founder, in a variety,of public relations ...
... 26 InterMune, Inc.,(Nasdaq: ITMN ) today ... shares of common stock at a price to ... of common stock, representing the exercise,by the underwriters ... the,offering. The net proceeds to the company of ...
... Sept. 26 Advanced Bio-Technologies,Inc (ABT) is pleased to ... purchased by HealthEdge Investment Partners of Tampa,FL. (http://www.healthedgepartners.com ... "This is a new stage,in the exciting development of ... marketing in the USA, build the necessary infrastructure for ...
Cached Biology Technology:Immunotec Inc. announces retirement of President & CEO C.H. (Chuck) Roberts 2InterMune Announces Closing of Public Offering of Common Stock 2Advanced Bio-Technologies Inc Announces Acquisition by HealthEdge Investment Partners, Tampa FL 2
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... Conn. , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... new advertising campaign on CNBC television starting March 30 th ... will commence airing in New York ... Officer said: "We are excited about our new ad campaign ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... 2009) -- A husband and wife team of American paleontologists has ... ago during the early Cretaceous of central Montana. The new ... of the Canadian Journal of Earth Sciences . Ankylosaurs are ... a plate-like armour with two sets of sharp spikes on each ...
... decades, climate scientists have worked to identify and measure key ... affect Earth,s climate. And they,ve been aided by ever more ... each type of pollutant more reliable. Yet the ... it -- continues to serve up surprises. The most recent? ...
... KATHMANDU, October 30 - China received praise here today from ... its neighbors to end tiger trade and bring back wild ... opposed to tiger trade from any source, praised comments by ... the Kathmandu Global Tiger Workshop, who pledged to replace the ...
Cached Biology News:New dinosaur species from Montana 2Interactions with aerosols boost warming potential of some gases 2Interactions with aerosols boost warming potential of some gases 3Interactions with aerosols boost warming potential of some gases 4Asia's biggest 'tiger' unviels promise for wild tigers 2
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... Yellow crystalline solid. PROTECT FROM LIGHT. Useful in ... required. Purity: ≥98% by TLC. Soluble in ... preparation of a 10 mM stock in DMSO is ... to H 2 O with rapid mixing (e.g. 10 ...
... IgM binds poorly to Protein A and, ... existed for one- step IgM purification. Standard methods ... or they are not effective for removing all ... Pierce has developed ...
... 3′-(α-Amino- p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl ... FROM MOISTURE. Protein synthesis inhibitor. Inhibits ... nascent polypeptide chains. Induces DNA fragmentation ... leukemia cells. Purity: ≥98% by ...
Biology Products: